These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 61475)

  • 21. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. III. Effect of C. parvum on cyclophosphamide metabolism.
    Fisher B; Wolmark N; Rubin H
    J Natl Cancer Inst; 1976 Jul; 57(1):225-6. PubMed ID: 1003505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant intralesional and systemic Corynebacterium parvum immunotherapy for surgically treated head and neck cancer.
    Beatty JD; Terz JJ; Brown PW; Lawrence W; Schuller GB; Kaplan AM
    Surg Forum; 1978; 29():155-7. PubMed ID: 401122
    [No Abstract]   [Full Text] [Related]  

  • 23. Corynebacterium parvum as a therapeutic antitumor agent in mice. II. Local injection.
    Scott MT
    J Natl Cancer Inst; 1974 Sep; 53(3):861-5. PubMed ID: 4213016
    [No Abstract]   [Full Text] [Related]  

  • 24. Proceedings: Treatment of a metastasizing murine tumour with Corynebacterium parvum.
    Sadler TE; Castro JE
    Br J Cancer; 1975 Feb; 31(2):264. PubMed ID: 1164486
    [No Abstract]   [Full Text] [Related]  

  • 25. [Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)].
    Mayr AC; Senn HJ; Gallmeier WM; Bruntsch U; Becher R; Drings P; Fritze D; Kaufmann M; Queisser W; Kempgens U
    Dtsch Med Wochenschr; 1979 Dec; 104(49):1739-43. PubMed ID: 510206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corynebacterium parvum as a therapeutic antitumor agent in mice. I. Systemic effects from intravenous injection.
    Scott MT
    J Natl Cancer Inst; 1974 Sep; 53(3):855-60. PubMed ID: 4213015
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of prolonged Corynebacterium parvum and cyclophosphamide administration on spontaneously occurring metastases.
    Wolmark N; Fisher B
    Surg Forum; 1975; 26():136-8. PubMed ID: 1216089
    [No Abstract]   [Full Text] [Related]  

  • 28. Lasting rejection of mammary adenocarcinoma cell tumors in DBA-2 mice with intratumor injection of killed Corynebacterium parvum.
    Likhite VV; Halpern BN
    Cancer Res; 1974 Feb; 34(2):341-4. PubMed ID: 4810906
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunological studies in patients receiving Corynebacterium parvum (C.P.) as immunotherapy for acute myelogenous leukemia (AML).
    Pai VR; Shetty PA; Jussawalla DJ
    Indian J Cancer; 1982; 19(3):149-52. PubMed ID: 6959958
    [No Abstract]   [Full Text] [Related]  

  • 30. Corynebacterium parvum: a synonym for Propionibacterium acnes?
    Cummins CS; Johnson JL
    J Gen Microbiol; 1974 Feb; 80(2):433-42. PubMed ID: 4826546
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of Corynebacterium parvum on human effector cells in peripheral blood.
    Gill PG; Waller CA; Clarke J; Darley J; Morris PJ
    Dev Biol Stand; 1977 Apr 13-15; 38():455-60. PubMed ID: 608538
    [No Abstract]   [Full Text] [Related]  

  • 32. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
    Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
    Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Organ distribution of technetium-99m-labeled corynebacterium parvum in normal and tumor-bearing mice.
    Barth RF; Singla O
    Cancer Res; 1978 Jan; 38(1):32-4. PubMed ID: 618580
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical trial with Corynebacterium parvum.
    Medenica R; Girard JP; Maurice P
    Dev Biol Stand; 1977 Apr 13-15; 38():483-5. PubMed ID: 344103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coagulation and fibrinolysis during the infusion of Corynebacterium parvum in man.
    Cederholm-Williams SA; King A; Allington MJ; Gill PG; Sharp AA; Britton BJ
    Br J Cancer; 1978 Jun; 37(6):1074-7. PubMed ID: 678428
    [No Abstract]   [Full Text] [Related]  

  • 36. Proceedings: Therapy of methyl cholanthrene induced CBA mouse tumours with Corynebacterium parvum and irradiated tumour cells.
    Bomford R
    Br J Cancer; 1975 Aug; 32(2):241. PubMed ID: 1212356
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of efficacy of mitomycin-C and corynebacterium parvum in the management of malignant pleural effusion.
    Yew WW; Chan SL; Kwan SY
    Chin Med J (Engl); 1988 Oct; 101(10):737-9. PubMed ID: 3150706
    [No Abstract]   [Full Text] [Related]  

  • 38. [Stimulating immunity with the use of Corynebacterium parvum after resection of carcinoma of bronchial origin. Clinical aspects].
    Dangubić V; Dujić A; Lilić D; Kolasinović N; Jeremić K
    Srp Arh Celok Lek; 1982 Sep; 110(9):1017-24. PubMed ID: 7182936
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of intracerebral administration of Corynebacterium parvum on the growth of brain tumors in mice.
    Kiya K; Toge T; Harada K; Uozumi T; Hattori T
    Gan; 1981 Jun; 72(3):446-50. PubMed ID: 7319201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunopotentiation in the treatment of malignant diseases. Cellular immunity in patients with malignoma of the lung treated with Corynebacterium parvum].
    Dujić A; Dangubić V; Lilić D; Kolasinović N
    Vojnosanit Pregl; 1982; 39(4):298-301. PubMed ID: 7147792
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.